Histone Deacetylase Inhibitors Research

SEP 10, 2026 · JOURNAL ARTICLE

ECT2 antagonizes lipoic acid to modulate papillary thyroid carcinoma progression through energy metabolism pathways

Cancer Cell International

Mechanistic in vitro study in cell lines with RNA sequencing showing ECT2's role in PTC proliferation and drug resistance; lacks in vivo validation, clinical trial data, or prospective patient outcomes.

SEP 10, 2026 · JOURNAL ARTICLE

Regulatory roles of five key USP family deubiquitinases in cancer: from mechanisms to targeted therapy advances

Frontiers in Pharmacology

A systematic narrative review of mechanistic literature on five deubiquitinases in cancer, proposing therapeutic targeting strategies without reporting clinical trial data or empirical evidence of efficacy.

SEP 9, 2026 · JOURNAL ARTICLE

Ribitoborate Synergism with Histone Deacetylase Inhibitor Romidepsin as a Potential Treatment for Breast Cancer

International Journal of Molecular Sciences

In vitro mechanistic study in a single TNBC cell line suggesting synergy between two agents, lacking any in vivo validation, patient data, or clinical trial evidence to support therapeutic application.

SEP 8, 2026 · JOURNAL ARTICLE

An AI-Assisted Workflow for Rapid Prioritization of FDA-Approved Drugs as HDAC3 Inhibitor Candidates for Drug Repurposing

Biology

This is an exploratory computational study using machine learning to predict HDAC3 inhibition by FDA-approved drugs, without experimental validation or clinical data, raising mechanistic questions rather than answering therapeutic ones.

SEP 8, 2026 · JOURNAL ARTICLE

Translational advances in p53 targeted cancer therapy from molecular mechanisms to clinical application

Discover Oncology

A narrative review evaluating translational barriers to p53-targeted therapy, raising mechanistic questions and proposing future directions rather than reporting a new trial result or establishing clinical efficacy.

SEP 7, 2026 · JOURNAL ARTICLE

Anticancer Enzyme Inhibition Potential of Organosulphur Compounds via Histone Deacetylase, Carbonic Anhydrase, and Xanthine Oxidase Inhibition

European Journal of Biology

In vitro enzyme inhibition study of organosulfur compounds against three targets; no cellular, animal, or clinical validation reported, and no comparison to established drugs or positive controls.

SEP 7, 2026 · JOURNAL ARTICLE

PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy

Cancer Drug Resistance

This is a narrative review synthesizing preclinical mechanistic evidence and proposing PSMD14 as a therapeutic target, but it does not report new empirical data, clinical trials, or outcomes in patients.

SEP 4, 2026 · JOURNAL ARTICLE

Structure-based discovery of coumarin-derived HDAC2 inhibitor through integrated computational bioassays, steered molecular dynamics, network analysis and SAR

Main Group Chemistry

Structure-based computational discovery of a novel HDAC2 inhibitor with predicted superior binding and activity; lacks experimental validation in cells or organisms, representing early-stage hypothesis-generating work.